Claim 1: A group of antibodies consisting of (1) antibodies and (2) hyaluronic acid polymers covalently bind to the antibody.1. Polymer dispersion index (PDI) of A is 1.1 or less. Claim 19: The total number of antibodies in any claim 1-18,A. The antibody binds to a specific biological molecule, which is composed of vascular endocrine growth factor (VEGF).1. IL-1B；I-6；IL-6R；I-13；- 13R；PDGF；Angiography；2. AngiopoyetinaParagraph 2Page: 1AVB3 protoplastAVB5 and A5B1；Betacelulina；1. Appeal/People's Court；Erythromycin；Cofactor D；TNFA；Htra1；A vegetarianST-2 receptors and proteins genetically associated with AMD risk. Claim 22: Consolidated antibodies in claim 19,There, the antibody specifically binds to Vegf. Claim 23: Consolidated antibodies in claim 22,The antibody consists of the following six variable regions: (a) an HVR-H1, including the Dywih amino acid sequence (SEQ ID No.1)；(b) HVR-H2, including GX1-TPXGX3 X8308； X8309； (YX8310 DSVX8311； X-831222 (SEQ ID No.2)；If you have registered, please login first.X2 is ALA or ARG.X3 is Tyr or LysX83088 is THR or GLU.X830909 is ARG.Thailand...GLN or GLU,X8310 is a wing or GLU.X degree 8311 is Lys or GLU.X831222 is GLY or GLU；(c) HVR-H3, including Fvfflpyamdy amino acid sequence (SEQ ID No.3)；(d) HVR-L1, including the amino acid sequence of Rasqx1 vstava (SEQ ID No.4),X1 is the place of ASP or ARG；(e) HVR-L2, including X1 ASFrys amino acid sequence (SEQ ID No.5),Anyone can view this photo.(f) HVR-L3, including the amino acid sequence of X1 QGYXPFT (SEQ ID No.6)；In X1, it's GLN.ASN or THR,This is Ala.ASN,GLN or ARG. Claim 123: The pharmaceutical ingredients used in any 106-121 claim for the production of medicines for the treatment of eye diseases in patients.Reivindicación 1: Un conjugado de anticuerpo que comprende (i) un anticuerpo y (ii) un polímero de ácido hialurónico (HA) unido de forma covalente al anticuerpo, en donde el polímero de HA tiene un índice de polidispersión (PDI) de 1,1 o menos. Reivindicación 19: El conjuga
